1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. ATYR PHARMA INC
Atyr Pharma Inc
XNAS: ATYR
Download real time
0.290.00(0.00%)
New 52W Low today
1.8M
XNAS Volume

XNAS 05 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Atyr Pharma Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Atyr Pharma Inc share price target, revenues, EPS, net income and more

Atyr Pharma Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • NEUTRAL

    Quarterly Revenue Atyr Pharma Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.

  • POSITIVE

    Quarterly Net Profit Atyr Pharma Inc Jun-2026 Quarterly Net Profit is $-10 Million which is growth of 47.2% YoY.

Atyr Pharma Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
0.20.20.4
Cost Of Rev.
-------------
Gross Profit
-------------
⌄
10.911.414.826.920.315.815.818.117.316.9161313.6
Operating Profit
-10.9-11.4-14.8-26.7-20.3-15.8-15.8-18.1-17.3-16.6-16-12.6-13.6
⌄
-------------
Profit Before Tax
-10.3-10.8-14-25.8-19.5-14.9-15-17.3-16.3-15.5-14.8-11.3-12.3
Tax
-------------
⌄
-10.3-10.8-14-25.7-19.5-14.9-15-17.3-16.3-15.5-14.8-11.3-12.3
Diluted NI Avail to Com Stockholders Ann.
-10.3-10.8-14-25.7-19.5-14.9-15-17.3-16.3-15.5-14.8-11.3-12.3
Basic EPS
-0.1-0.1-0.1-0.3-0.2-0.2-0.2-0.2-0.2-0.2-0.3-0.2-0.2
Diluted EPS After ExtraOrdinary
-0.1-0.1-0.1-0.3-0.2-0.2-0.2-0.2-0.2-0.2-0.3-0.2-0.2
Number Of Shares End
98.19898.197.290.186.582.875.872.366.159.357.955.1
Net Income Continuing Discontinued Operations
-10.3-10.8-14-25.7-19.5-14.9-15-17.3-16.3-15.5-14.8-11.3-12.3
Normalized Income
-10.3-10.8-14-25.7-19.5-14.9-15-17.3-16.3-15.5-14.8-11.3-12.3
Interest Income
-------------
Interest
-------------
Net Interest Income
-------------
EBIT
-10.9-11.4-14.8-26.8-20.3-15.8-15.8-18.1-17.3-16.6-16-12.6-13.6
EBITDA
-10.5-11-14.4-26.4-19.9-15.4-15.8-17.8-16.9-15.9-15.6-11.6-13
Reconciled Cost Of Rev.
-------------
Reconciled Depr.
0.40.40.40.40.40.40.40.40.80.410.6
Profit From Continuing Operations
-10.3-10.8-14-25.8-19.5-14.9-15-17.3-16.3-15.5-14.8-11.3-12.3
Normalized EBITDA
-10.5-11-14.4-26.4-19.9-15.4-15.8-17.8-16.9-15.9-15.6-11.6-13
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Atyr Pharma Inc competitor comparison and performance snapshot within industry

Atyr Pharma Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Annual Revenue Atyr Pharma Inc Dec-2025 Annual Revenue is $0 Million which is growth of -19.1% YoY.

  • NEGATIVE

    Annual Net Profit Atyr Pharma Inc Dec-2025 Annual Net Profit is $-74 Million which is growth of -15.8% YoY.

Atyr Pharma Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-73.2%
-54.7%
 0.20.20.410.410.50.4
Cost Of Rev. Ann.
-
-
 -----------
Gross Profit Ann.
-
-
 -----------
Operating Exp. Ann.
11.1%
24.1%
6477.868.255.356.83426.423.432.847.157.947.6
Operating Profit Ann.
-
-
-63.9-77.6-67.9-54.9-46.4-34-15.9-23-32.8-47.1-57.9-47.6
⌄
-
-
 ---------0.1-0.4
Other Exp. Ann.
47.1%
-
 3.53.94.51.10.2-0.3-0.8-1.7-1.1-00
PBT Ann.
-
-
-60.8-74.1-64-50.4-45.3-33.8-16.2-23.8-34.5-48.2-57.9-48
Tax Ann.
-
-
 ---------0.1-
⌄
-
-
-60.8-74.1-64-50.4-45.3-33.8-16.2-23.6-34.5-48.2-57.9-48
Diluted NI Avail to Com Stockholders Ann.
-
-
-60.8-74.1-64-50.4-45.3-33.8-16.2-23.6-34.5-48.2-57.9-48
EPS Ann.
-
-
 -0.8-0.9-0.9-1.6-1.8-1.8-7-16.1-26.2-34.2-42.4
Diluted EPS Ann.
-
-
 -0.8-0.9-0.9-1.6-1.8-1.8-7-16.1-26.2-34.2-42.4
Number Of Shares End
49.9%
55.8%
 98.182.859.329.127.910.73.92.22.11.71.7
Total Exp. Ann.
11.1%
24.1%
 77.868.255.356.83426.423.432.847.157.947.6
Net Income Continuing Discontinued Operations Ann.
-
-
-60.8-74.1-64-50.4-45.3-33.8-16.2-23.6-34.5-48.2-57.9-48
Normalized Income Ann.
-
-
-60.8-74.1-64-50.4-45.3-33.8-16.2-23.6-34.5-48.2-57.8-48
Interest Income Ann.
-
-
 -----------
Interest Ann.
-
-
 -----------
EBITDA Ann.
-
-
-62.3-76.1-66.4-52.2-44.7-32.7-14.6-21.6-32.1-46.4-57-46.8
Reconciled Cost Of Rev. Ann.
-
-
 -----------
Reconciled Depr. Ann.
-2%
4.2%
1.61.61.52.71.71.31.31.40.80.70.90.9
Profit From Continuing Operations Ann.
-
-
-60.8-74.1-64-50.4-45.3-33.8-16.2-23.8-34.5-48.2-57.9-48
Normalized EBITDA Ann.
-
-
-62.3-76.1-66.4-52.2-44.7-32.7-14.6-21.6-32.1-46.4-57-46.8
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Rev. Ann.
2Y CAGR
-29.3%
3Y CAGR
-73.2%
5Y CAGR
-54.7%
Total Revenue Annual is falling faster than historical averages.
Operating Exp. Ann.
1Y CHG
14.1%
2Y CAGR
18.6%
3Y CAGR
11.1%
5Y CAGR
24.1%
7Y CAGR
13.1%
10Y CAGR
5%
Operating Expenses Annual Cr growth is stable compared to historical averages.

Atyr Pharma Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Total Shareholders Fund Atyr Pharma Inc Dec-2025 Total Shareholders Fund is $67 Million which is growth of -3.6% YoY.

  • NEGATIVE

    Total Assets Atyr Pharma Inc Dec-2025 Total Assets is $93 Million which is growth of -4.0% YoY.

Atyr Pharma Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-1%
19.2%
9396.8120.795.8115.538.736.252.889.480.5129.7
⌄
1.6%
29%
25.72730.224.56.47.215.219.125.117.714.6
⌄
-1.9%
16.3%
67.57090.771.5109.331.721.233.764.262.8115.1
Total Capitalization Ann.
-1.9%
16.3%
67.57090.771.5109.331.721.241.97972116.8
Tangible Assets Ann.
-1.9%
16.3%
67.57090.771.5109.331.721.233.764.262.8115.1
Working Capital Ann.
-1%
17%
65.16786.667107.629.7194076.666.285.8
Invested Capital Ann.
-1.9%
16.3%
67.57090.771.5109.331.729.949.78472.3120.2
Tangible Book Value Ann.
-1.9%
16.3%
67.57090.771.5109.331.721.233.764.262.8115.1
Borrowings Ann.
1.4%
40.4%
1213.315.111.51.42.211.71619.79.55.1
Net Debt Ann.
-
-
-----------
Share Issued Ann.
49.2%
54.9%
988463.329.527.8113.92.22.11.71.7
Number Of Shares End
49.9%
55.8%
98.182.859.329.127.910.73.92.22.11.71.7
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
-3.9%
2Y CAGR
-12.2%
3Y CAGR
-1%
5Y CAGR
19.2%
7Y CAGR
8.4%
10Y CAGR
-3.3%
Total Assets Annual is falling faster than historical averages.
Total Current Liabilities Ann.
1Y CHG
1.3%
2Y CAGR
-3.7%
3Y CAGR
3%
5Y CAGR
20.8%
7Y CAGR
5%
10Y CAGR
2.2%
Total Current Liabilities Annual Cr growth is lower than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
-3.6%
2Y CAGR
-13.7%
3Y CAGR
-1.9%
5Y CAGR
16.3%
7Y CAGR
10.4%
10Y CAGR
-5.2%
Total ShareHolders Funds Annual is falling faster than historical averages.

Atyr Pharma Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Book Value Per Share Atyr Pharma Inc Book Value Per Share is $0 which is growth of -36.0% YoY.

  • NEUTRAL

    ROE Atyr Pharma Inc ROE is 0% which is growth of 0% YoY.

Atyr Pharma Inc, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
RoA Ann. %
-
-
--58.88%-46.56%-42.91%-43.78%-43.31%-53.08%-48.58%-56.75%-55.05%-63.85%
ROE Ann. %
-
-
--79.69%-62.16%-50.16%-47.91%-61.42%-86.09%-70.52%-75.89%-65.06%-79.99%
ROIC %
-
-
--18.5-13.5-8.9-7.5-13.8-16.3-11.9-13.4-15.9-12.9
OPM Ann. %
-
-
-40,856.32%-28,899.57%-15,557.79%-446.79%--152.19%-5,445.02%----
Inventory Turnover Ratio Ann.
-
-
-----------
Asset Turnover Ann. %
-
-
-0.1-0.30----
Working Capital Turnover Ann.
-
-
0.20.40
Quick Ratio Ann.
-
-
-4.96.15.6185.82.44.68.28.57.9
Current Ratio Ann.
-
-
-5.56.35.818.96.12.54.78.48.88.1
Interest Coverage Ratio Ann.
-
-
-----------
LT Debt To Equity Ann.
-
-
-0.20.20.200.10.30.20.20
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Atyr Pharma Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Cash From Operating Activity Atyr Pharma Inc Dec-2025 Cash From Operating Activity is $-62 Million which is growth of 10.3% YoY.

  • POSITIVE

    Net Cash Flow Atyr Pharma Inc Dec-2025 Net Cash Flow is $-1 Million which is growth of 91.4% YoY.

Atyr Pharma Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-
-
-62-69.1-33.2-41.9-33.1-15.3-20-31.1-42.4-52.9-36.8
⌄
-
-
-5.117.2-20.147.2-91.66.94.937.2-27.633.5-72
⌄
128.9%
32.6%
6639.966.25.511016.11.3-4.252.74.7147.9
Cash Plus Cash Eqv. End Of Year Ann.
-0.5%
-5.2%
13142613.22.3179.22321.138.453
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-
-1-1212.910.8-14.67.7-13.81.9-17.3-14.639.1
Cash Plus Cash Eqv. Begin Of Year Ann.
82.6%
8.8%
142613.22.3179.22321.138.45313.9
Income Tax Paid Supplemental Data Ann.
-
-
-----------
Interest Paid Supplemental Data Ann.
0%
-19.7%
0.10.10.20.10.31.11.710.20.9
Capex Ann.
-
-
-0.1-0.1-4.2-1.6-0.2-0.2-0.1-0.6-1.3-0.6-0.7
Issuance Of Capital Stock Ann.
129.4%
21.4%
66.440.366.55.511025.29.30.442.5152.6
Issuance Of Debt Ann.
-
-
------9.99.7
Repayment Of Debt Ann.
-
-
-0.5-0.5-0.4-0.1-9.1-8-4.7--5.2-5.2
Repurchase Of Capital Stock Ann.
-
-
-----------
Free Cash Flow Ann.
-
-
-62.1-69.2-37.4-43.5-33.3-15.5-20.1-31.7-43.7-53.5-37.5
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Financing Act. Ann.
1Y CHG
65.4%
2Y CAGR
-0.2%
3Y CAGR
128.9%
5Y CAGR
32.6%
10Y CAGR
-7.8%
Cash from Financing Annual Activity growth is stable compared to historical averages.
×